Altered C-Fiber Function as an Indicator of Early Peripheral Neuropathy in Individuals With Impaired Glucose Tolerance by Green, Alistair Q. et al.
Altered C-Fiber Function as an Indicator of
Early Peripheral Neuropathy in Individuals
With Impaired Glucose Tolerance
ALISTAIR Q. GREEN, MRCP
1
SINGHAN KRISHNAN, MD, MRCP
1 FRANCIS M. FINUCANE, MD, MRCPI
2
GERRY RAYMAN, MD, FRCP
1
OBJECTIVE — This study explored the importance of glycemic burden compared with fea-
tures of the metabolic syndrome in the pathogenesis of diabetic neuropathy by comparing
C-ﬁberfunctioninpeoplewithtype1diabetestothatinpeoplewithimpairedglucosetolerance
(IGT).
RESEARCH DESIGN AND METHODS — The axon reﬂex–elicited ﬂare areas (LDI-
ﬂares) were measured with a laser Doppler imager (LDI) in age-, height-, and BMI-matched
groups with IGT (n  14) and type 1 diabetes (n  16) and in healthy control subjects (n  16).
RESULTS — The ﬂare area was reduced in the IGT group compared with the control (2.78 
1.1 vs. 5.23  1.7 cm
2, P  0.0001) and type 1 diabetic (5.16  2.3 cm
2, P  0.002) groups,
whereas the ﬂare area was similar in the type 1 diabetic and control groups.
CONCLUSIONS — This technique suggests that small-ﬁber neuropathy is a feature of IGT.
The absence of similar small-ﬁber neuropathy in those with longstanding type 1 diabetes sug-
gests that glycemia may not be the major determinant of small-ﬁber neuropathy in IGT.
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mall nerve ﬁbers are lost early in the
naturalhistoryoftype2diabetes(1–
3). A recent study of individuals
with idiopathic neuropathy, but normal
glucose tolerance, found the majority had
features of the metabolic syndrome (4).
Given that small-ﬁber neuropathy is ap-
parent in pre-diabetic and insulin resis-
tant states, the relative importance of
hyperglycemiaperse,asopposedtoother
metabolic factors, is unclear. Indeed, re-
cent studies have shown associations be-
tween neuropathy and traditional
cardiovascular risk factors such as BMI
andlipidsinpre-andestablisheddiabetes
(5,6).
This study explored the importance
of glycemic burden versus metabolic fac-
tors in the pathogenesis of diabetic small-
ﬁber neuropathy by using the axon
reﬂex–elicited ﬂare area (LDIﬂare) tech-
nique to assess C-ﬁber function in sub-
jects with impaired glucose tolerance
(IGT) and type 1 diabetes with minimum
or no microvascular complications, the
latterrepresentingindividualswithahigh
glycemic burden without signiﬁcant neu-
ral microangiopathy. The LDIﬂare tech-
nique measures the area of neurogenic
vasodilatation induced by heat with a la-
ser Doppler imager (LDI) (Moor Instru-
ments, Devon, U.K.). The test has good
reproducibility and correlates with nerve
ﬁber density (1,7).
RESEARCH DESIGN AND
METHODS— LDIﬂares were mea-
sured in age-, height-, and BMI-matched
groups of type 1 diabetic (n  16), IGT
(n  14), and healthy control (n  16)
subjects. The latter groups were con-
ﬁrmed by an oral glucose tolerance test.
Thosewithtype1diabetespresentedwith
a typical history or ketoacidosis and were
treated with insulin from diagnosis. Sub-
jects with ankle brachial pressure indexes
of 0.8 were excluded. Subjects were as-
sessed for metabolic syndrome using the
International Diabetes Federation criteria
(8).
Assessment of the LDIﬂare
After 20 min acclimatizing in a tempera-
ture-controlled room (25  1°C), the
neurogenicﬂarewasinducedbyheatinga
1-cm diameter area on the dorsum of the
foot to 44°C for 20 min. The area was
scanned using the imager, and the ﬂare
area was identiﬁed (with a hyperemic re-
sponse 300 PU) and measured. Addi-
tionally, the maximum hyperemia
(LDImax) in the skin immediately be-
neath the heater was measured using
the imager. Unlike the ﬂare, LDImax is
mediated by nonneurogenic means and
reﬂects maximum microvascular hyper-
emia (1). In all subjects clinical neuropa-
thy was excluded using the neuropathy
disability scale (9); vibration perception
thresholds (neurothesiometer); and
quantitative sensory testing of warming,
cooling, and vibration perception (Com-
puter Aided Sensory Evaluator IV).
Statistical analysis
LDIﬂare and LDImax were expressed as
means  SD. The means were compared
sequentially with ANOVA and then with
Student t tests. Variables were correlated
using Pearson coefﬁcient. With coefﬁ-
cients of variation (CVs) for LDIﬂare and
LDImax conservatively estimated at 20%
(actual CVs: LDIﬂare, 13%; LDImax,
6%), a prestudy power calculation sug-
gested 16 participants per group would
detect a 20% difference with 80% power.
RESULTS— Group characteristics
and results are summarized in Table 1.
TheLDIﬂarewassigniﬁcantlylowerinthe
IGT compared with the control (2.78 
1.1 vs. 5.23  1.7 cm
2, P  0.0001) and
type 1 diabetic (5.16  2.3 cm
2, P 
0.002) groups. In contrast, the LDIﬂares
of the type 1 diabetic and control groups
were not different. LDImax was reduced
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group. There was no correlation between
LDImax and LDIﬂare either within
groups or when combined. The relatively
favorable lipid proﬁle in the diabetic
group may be related to greater use of lip-
id-lowering therapy. In the combined
IGT and healthy control groups, fasting
triglycerides (r  0.39; P  0.044) and
2-h glucose (r  0.48; P  0.0066)
were inversely correlated with LDIﬂare.
CONCLUSIONS — This study has
yielded several important ﬁndings. First,
the LDIﬂare technique detects early
small-ﬁber dysfunction when conven-
tional tests, including Computer Aided
SensoryEvaluatorIV,arenormal.Thepo-
tential for earlier detection and the non-
invasive nature of the method are
advantages over existing techniques such
as skin biopsy, particularly when re-
peated measurements are required.
Second, the detection of small-ﬁber
dysfunctioninthefeetintheIGTgroupis
consistent with other studies but is novel
in that functional rather than structural
integrity was examined (10–12). Given
thatfunctionaldefectsmayprecedestruc-
tural changes and are more likely to be
reversible, the method may be particu-
larlyvaluableinassessinginterventionsto
prevent or delay progress of neuropathy.
Further studies comparing LDIﬂare tech-
nique with other functional tests such as
cardiac autonomic function and the
newer structural techniques, intraepider-
mal and corneal nerve ﬁber density,
would help determine its relative value.
Third, small-ﬁber dysfunction in the
IGT group contrasts with the apparent
normality in the type 1 diabetic subjects.
The latter group was unusual, being rela-
tively free from complications, but this
was necessary to exclude endoneural mi-
croangiopathy, which itself is associated
with neuropathy (13). It is possible that
other tests such as cardiac autonomic
function may have been abnormal in this
group. The difference in small-ﬁber func-
tion between these two groups suggests
factors other than hyperglycemia are im-
plicatedinthedevelopmentofsmall-ﬁber
dysfunction. The signiﬁcant association
withcertainfeaturesofthemetabolicsyn-
drome, namely 2-h glucose and triglycer-
ide levels, suggests a common metabolic
link.Furtherstudieswouldberequiredto
conﬁrm these suggestions.
The ﬂare, although dependent on in-
tactsmallﬁbers,requiressufﬁcientmicro-
vascular vasodilatation for it to be
detected by the imager. This was so in all
subjects, demonstrated by the LDImax
measurements. In this context, the ab-
sence of any correlation between LDImax
and LDIﬂare measurements conﬁrms that
they reﬂect different parameters. Addi-
tionally, LDIﬂare was undiminished in
the type 1 diabetic group despite, as ex-
pected from our previous study, a reduc-
tion in their LDImax (14). LDImax is
believed to reﬂect endothelial function
(15), and impaired endoneurial function
is implicated in the development of neu-
ropathy (13). However, that LDImax did
not correlate with small-ﬁber function
might indicate that endothelial dysfunc-
tion only affects neural function at more
advanced stages when there is signiﬁcant
microangiopathy.
In summary, the LDIﬂare technique
has adequate sensitivity to detect early
small-ﬁber dysfunction. The presence of
small-ﬁber dysfunction in those with IGT
and not in those with long-duration type
1 diabetes in the absence of signiﬁcant
microvascular disease suggests that fac-
tors other than hyperglycemia contribute
to small-ﬁber dysfunction in those with
IGT.
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